Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes

Scand J Gastroenterol. 1985 Jun;20(5):629-35. doi: 10.3109/00365528509089708.


A double-blind, placebo-controlled trial was performed, using 400-mg cimetidine tablets or placebo twice daily for 4 weeks in 100 patients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) grade 2 or 3. Symptomatic assessment was made weekly and endoscopic assessment on completion of the treatment period. Symptomatically, a significant effect of cimetidine versus placebo on epigastric pain/discomfort was recorded after 2 weeks' treatment (p less than 0.05). Endoscopically, there was a significant improvement, according to our grading scale of EPC, in the cimetidine-treated group, as compared to the placebo-treated group (p less than 0.05). On the basis of our findings, patients with NUD and EPC who have epigastric pain/discomfort as a prominent symptom seem to profit from treatment with cimetidine.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Cimetidine / therapeutic use*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Dyspepsia / diagnosis
  • Dyspepsia / drug therapy*
  • Female
  • Gastric Mucosa / pathology*
  • Gastritis / diagnosis
  • Gastritis / drug therapy*
  • Gastroscopy
  • Humans
  • Male
  • Middle Aged
  • Stomach Ulcer / diagnosis*


  • Cimetidine